

Appendix 2: Subgroup analyses in included studies (as supplied by the authors)

Table 1: Studies examining mortality among subgroups					
Author	Subgroup	eGFR category	No. patients	HR (95% CI)	Adjustment variables
Traynor ¹	Nondiabetics	≥ 8 mL/min GFR < 8 mL/min GFR	97 87	Not reported	
Kazmi ²	Age > 67 y	Per ↑ 1 mL/min GFR	91 083	M1: 1.040 (1.038–1.042) M2: 1.028 (1.026–1.030) M3: 1.028 (1.025–1.031) M4: 1.028 (1.025–1.031)	M1: adjusted for age, sex, race, Hispanic ethnicity, BMI, cause of kidney failure, year of initiation of dialysis, network; M2: M1 + comorbid conditions; M3: M2 + hematocrit and albumin; M4: M3 + employment and insurance status
	Low-risk population	Per ↑ 1 mL/min GFR	90 540	M1: 1.047 (1.044–1.050) M2: 1.041 (1.038–1.044) M3: 1.034 (1.029–1.039) M4: 1.031 (1.026–1.036)	M1: adjusted for age, sex, race, Hispanic ethnicity, BMI, cause of kidney failure, year of initiation of dialysis, network; M2: M1 + comorbid conditions; M3: M2 + hematocrit and albumin; M4: M3 + employment and insurance status
Coronel ³	Diabetics on PD	> 7.7 mL/min/1.73 m ² ≤ 7.7 mL/min/1.73 m ²	56 44	Not reported	
Stel (1999 cohort) ⁴	Age	Per ↑ 1 mL/min/1.73 m ²	4644†‡		Age at start of dialysis, gender, primary renal disease, treatment modality, and country
	20–44 y			1.04 (0.99–1.09)	
	45–64 y			1.05 (1.03–1.06)	
	65–74 y			1.04 (1.03–1.06)	
	> 75 y	1.03 (1.02–1.04)			
Sex	Per ↑ 1 mL/min/1.73 m ²	4644		Same as above	
Female			1.03 (1.01–1.05)		
Male		1.04 (1.03–1.05)			
Comorbidity	Per ↑ 1 mL/min/1.73 m ²	4644		Same as above	
DM			1.04 (1.02–1.05)		
RVD/HTN			1.05 (1.03–1.06)		
GN			1.03 (1.00–1.06)		
Other		1.05 (1.03–1.06)			
Stel (2003 cohort) ⁴	Age	Per ↑ 1 mL/min/1.73 m ²	M1: 6613† M2: 3375‡		M1: age at start of dialysis, gender, primary renal disease, treatment modality, and country; M2: M1 + diabetes, heart disease, PVD, cerebrovascular disease, malignancy
	20–44 y		M1: 1.11 (1.05–1.17); M2: 1.12 (1.03–1.22)		
	45–64 y		M1: 1.04 (1.02–1.06); M2: 1.05 (1.03–1.07)		
	65–74 y		M1: 1.02 (1.01–1.04); M2: 1.02 (0.99–1.04)		
	> 75 y	M1: 1.02 (1.01–1.03); M2: 1.01 (0.98–1.03)			
Sex	Per ↑ 1 mL/min/1.73 m ²	M1: 6613 M2: 3375		Same as above	
Female			M1: 1.02 (1.00–1.03); M2: 1.01 (0.99–1.04)		
Male		M1: 1.03 (1.02–1.04); M2: 1.03 (1.01–1.05)			

Table 1: Studies examining mortality among subgroups

Author	Subgroup	eGFR category	No. patients	HR (95% CI)	Adjustment variables
	Comorbidity DM RVD/HTN GN Other	Per ↑ 1 mL/min/1.73 m ²	M1: 6613 M2: 3375	M1: 1.02 (1.00–1.04); M2: 1.00 (0.99–1.04) M1: 1.02 (1.00–1.05); M2: 1.03 (1.00–1.07) M1: 1.10 (1.05–1.15); M2: 1.11 (1.05–1.18) M1: 1.02 (1.01–1.03); M2: 1.02 (1.00–1.04)	Same as above
	Dialysis HD PD	Per ↑ 1 mL/min/1.73 m ²	M1: 6613 M2: 3375	M1: 1.02 (1.02–1.04); M2: 1.02 (1.01–1.04) M1: 1.03 (1.01–1.05); M2: 1.03 (1.00–1.05)	Same as above
Lassalle ⁵	Planned HD Planned PD Unplanned	Per ↑ 5 mL/min/1.73 m ²	6672 1367 3646	M1: 1.26 (1.19–1.34); M2: 1.13 (1.07–1.20); M3: 1.12 (1.06–1.19) M1: 1.16 (1.05–1.29); M2: 0.98 (0.88–1.10); M3: 1.00 (0.89–1.12) M1: 1.20 (1.13–1.26); 1.09 (1.03–1.15); M3: 1.08 (1.03–1.15)	M1: age and gender; M2: M1 + diabetes, heart failure, dysrhythmia, PVD, CHD, malignancy, severe disability; M3: M2 + predialysis anemia care, initial treatment condition, wait listing or transplantation
Cooper ⁶	Age < 60 y ≥ 60 y Sex Female Male Diabetes No Yes Albumin < 35 g/L ≥ 35 g/L	10–14 5–7 10–14 5–7 10–14 5–7 10–14 5–7 10–14 5–7	180 194 224 230 143 143 261 281 232 241 172 183 68 81 325 336	39/180§ 38/194 (not significant) 113/224 117/230 (not significant) 55/143 58/143 (not significant) 97/261 97/281 (not significant) 65/232 63/241 (not significant) 87/172 92/183 (not significant) 38/68 44/81 (not significant) 110/325 109/336 (not significant)	Unadjusted

Table 1: Studies examining mortality among subgroups

Author	Subgroup	eGFR category	No. patients	HR (95% CI)	Adjustment variables	
Wright ⁷	Age < 75 y	> 15	651 304	1.48 (1.46–1.49)	Age at ESRD onset, height and weight at ESRD onset, race, sex, diabetic status, Charlson comorbidity index, duration of predialysis nephrology care, type of dialysis, type of vascular access, cause of ESRD	
		10–15		1.17 (1.16–1.17)		
		5–10		Reference		
		≤ 5		0.86 (0.85–0.86)		
	≥ 75 y	> 15	243 989	1.35 (1.33–1.37)		Same as above
		10–15		1.11 (1.10–1.26)		
		5–10		Reference		
		≤ 5		0.96 (0.94–0.97)		
	Dialysis PD	> 15	63 691	1.42 (1.37–1.47)		Same as above
		10–15		1.10 (1.07–1.12)		
		5–10		Reference		
		≤ 5		0.96 (0.93–0.99)		
	HD	> 15	801 685	1.49 (1.47–1.50)		Same as above
		10–15		1.17 (1.16–1.17)		
5–10		Reference				
≤ 5		0.87 (0.86–0.87)				
Charlson comorbidity index	< 6	> 15	204 208	1.46 (1.42–1.5)	Same as above	
		10–15		1.18 (1.16–1.21)		
		5–10		Reference		
		≤ 5		0.84 (0.83–0.85)		
	6–8	> 15	468 446	1.46 (1.44–1.48)		Same as above
		10–15		1.15 (1.14–1.16)		
		5–10		Reference		
		≤ 5		0.90 (0.89–0.91)		
	> 8	> 15	222 639	1.37 (1.35–1.39)		Same as above
		10–15		1.13 (1.11–1.14)		
		5–10		Reference		
		≤ 5		0.94 (0.92–0.95)		
Rosansky (2011) ⁸	Albumin ≥ 3.5 g/dL- HD only	0–4.9	35 665 [†]	Reference	Not specified	
		5.0–9.9		1.27		
		10.0–14.9		1.53		
		≥ 15.0		2.18		

Table 1: Studies examining mortality among subgroups

Author	Subgroup	eGFR category	No. patients	HR (95% CI)	Adjustment variables
Kim ⁹	Dialysis HD	< 5	47	Not detailed—(read off graph); significant difference at 60 months	Unadjusted
		≥ 5	61		
	PD	< 5	52	Not detailed (read off graph); no significant difference at 60 months	Unadjusted
		≥ 5	50		
Collins ¹⁰	HD	10–14	171	Reference	
		5–7	191	0.97 (0.66–1.41)	
Rosansky (2009) ¹¹	Age 65–74 y	5–9.9 > 15		Not provided	
Wilson ¹²	HD only	< 5.0	46	Reference	Sex, age, months at CKD clinic, comorbidity (cardiac disease, PVD, diabetes, antihypertensive use)
		5.0–10.0	180	1.58 (0.54–4.65) [¶]	
		> 10.0	45	1.68 (0.65–4.32)	
Tang ¹³	PD only	Per ↓ 1 mL/min/1.73 m ²	233	1.53 (1.20–3.99)	Age, gender, diabetic status
Shiao ¹⁴	PD only	Per ↑ 1 mL/min/1.73 m ²	275	1.18 (1.02–1.37)	Age, sex, level of education, occupational activity, nephrology referral, implantation of catheters, initiation of dialysis, comorbidities (diabetes, CAD, congestive heart failure), lab data
Hwang ¹⁵	HD only	Per ↑ 1 mL/min/1.73 m ²	23 551	1.15 (1.14–1.17)	Age, sex, diabetes, GN, HTN, chronic TIN, CAD, CHF CVD, malignancy, liver cirrhosis, TB, dialysis initiation year
Clark ¹⁶	HD only	Per ↑ 1 mL/min/1.73 m ²	25 910	1.01 (1.01–1.02)	Age, sex, ethnicity, DM, GN, RVD, modified CMI score, CAD, CHR, HTN, CVD, PVD, lung disease, malignancy, albumin, vascular access, late referral

Note: BMI = body mass index; CAD = coronary artery disease; CHD: coronary heart disease; CHF = congestive heart failure; CKD = chronic kidney disease; CMI= Charlson Comorbidity Index; CVD = cardiovascular disease; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; ESRD = end-stage renal disease; GN = glomerulonephritis; HD = hemodialysis; HR = hazard ratio; HTN = hypertension; M = model; PD = peritoneal dialysis; PVD = peripheral vascular disease; RVD = renal vascular disease; TB = tuberculosis; TIN = tubulointerstitial nephritis.

*Without diabetes, congestive heart failure, or heart disease.

†Not presenting unadjusted analyses.

‡Number of patients in each subgroup not detailed for each model.

§Hazard ratio not written out (read off of table).

||Confidence intervals not presented.

¶Odds ratio, year 2 mortality (year 1 mortality not presented).

References

1. Traynor J, Simpson K, Geddes C, Deighan C, Fox J. Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. *J Am Soc Nephrol*. 2002;13:2125-32.
2. Kazmi W, Gilbertson D, Obrador G, et al. Effect of comorbidity on the increased mortality associated with early initiation of dialysis. *Am J Kidney Dis* 2005;46:887-96.
3. Coronel F, Cigarran S, Herrero J. Early initiation of peritoneal dialysis in diabetic patients. *Scand J Urol Nephrol* 2009;43:148-53.
4. Stel V, Dekker F, Ansell D, et al. Residual renal function at the start of dialysis and clinical outcomes. *Nephrol Dial Transplant* 2009;24:3175-82.
5. Lassalle M, Labeeuw M, Frimat L, et al. Age and comorbidity may explain the paradoxical association of an early dialysis start with poor survival. *Kidney Int* 2010;77.
6. Cooper B, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, et al. A randomized, controlled trial of early versus late initiation of dialysis. *N Engl J Med* 2010;363:609–19.
7. Wright S, Klausner D, Baird B, et al. Timing of dialysis initiation and survival in ESRD. *Clin J Am Soc Nephrol* 2010;5:1828-35.
8. Rosansky S, Eggers P, Jackson K, Glasscock R, Clark W. Early start of hemodialysis may be harmful. *Arch Intern Med* 2011;171:396-403.
9. Kim S, Kim N. The effect of residual renal function at the initiation of dialysis on patient survival. *Korean J Intern Med* 2009;24:55-62.
10. Collins J, Cooper B, Branley P, et al. Outcomes of patients with planned initiation of hemodialysis in the IDEAL trial. *Contrib Nephrol* 2011;171:1-9.
11. Rosansky S, Clark W, Eggers P, Glasscock R. Initiation of dialysis at higher GFRs: is the apparent rising tide of early dialysis harmful or helpful? *Kidney Int* 2009;76:257-61.
12. Wilson B, Harwood L, Locking-Cusolito H, et al. Optimal timing of initiation of chronic hemodialysis? *Hemodial* 2007;11:263-9.
13. Tang S, Ho Y, Tang A, et al. Delaying initiation of dialysis till symptomatic uraemia--is it too late? *Nephrol Dial Transplant* 2007;22:1926-32.
14. Shiao C, Huang J, Chien K, Chuang H, Chen Y, Wu K. Early initiation of dialysis and late implantation of catheters adversely affect outcomes of patients on chronic peritoneal dialysis. *Perit Dial Int* 2008;28:73-81.
15. Hwang S-J, Yang W-C, Lin M-Y, May L-W, Chen H-C, Taiwan Society of Nephrology. Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. *Nephrol Dial Transplant* 2010;25:2616-24.
16. Clark W, Na Y, Rosansky S, et al. Association between estimated glomerular filtration rate at initiation of dialysis and mortality. *CMAJ* 2011;183:47-54.